AKT1 and plasma cell myeloma: Furthermore, AUR exhibits inhibitory activity against cellular growth through various mechanisms, including the inhibition of the Janus kinase (JAK) 2/signal transducers and activators of transcription (STAT) 3 pathway in myeloma cells [31] and the phospho-inositide 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of the rapamycin (mTOR) pathway in non-small cell lung cancer cells [32].